Septerna (NASDAQ:SEPN – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other research analysts have also recently commented on the company. JonesTrading boosted their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wells Fargo & Company increased their target price on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Guggenheim increased their target price on Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Stifel Nicolaus raised their target price on Septerna from $49.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. Finally, JPMorgan Chase & Co. boosted their price target on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.44.
Check Out Our Latest Stock Report on Septerna
Septerna Stock Performance
NASDAQ SEPN opened at $42.60 on Friday. Septerna has a one year low of $19.69 and a one year high of $53.34. The company’s 50 day moving average price is $40.46 and its 200 day moving average price is $33.12. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -33.02 and a beta of 2.20.
Septerna (NASDAQ:SEPN – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%. The business had revenue of $18.88 million during the quarter, compared to analyst estimates of $20.78 million. Sell-side analysts forecast that Septerna will post -1.45 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $6,517,158.69. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Ezekowitz sold 81,820 shares of Septerna stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total value of $3,934,723.80. Following the sale, the director directly owned 35,600 shares in the company, valued at approximately $1,712,004. The trade was a 69.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 89,153 shares of company stock worth $4,210,451 in the last quarter. 5.80% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of SEPN. Renaissance Technologies LLC acquired a new position in Septerna during the 1st quarter worth $906,000. TRV GP V LLC bought a new stake in shares of Septerna in the 2nd quarter worth about $208,160,143. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Septerna in the 2nd quarter valued at about $445,000. First Light Asset Management LLC raised its stake in shares of Septerna by 31.4% in the 2nd quarter. First Light Asset Management LLC now owns 963,260 shares of the company’s stock valued at $32,260,000 after purchasing an additional 230,400 shares in the last quarter. Finally, TRV GP VI LLC acquired a new stake in shares of Septerna in the 2nd quarter valued at about $141,048,460.
Key Septerna News
Investors following SEPN have been watching these news items:
- Positive Sentiment: Analysts raised expectations for Septerna’s SEP-479 program, prompting a fair-value increase. The more optimistic outlook could support investors’ expectations for the company’s pipeline. Septerna fair-value lift as analysts raise SEP-479 expectations
- Positive Sentiment: Stifel Nicolaus raised its price target on SEPN, while another report said the shares reached a new 52-week high following an analyst upgrade—signals that may reinforce positive sentiment. Stifel Nicolaus price-target boost Shares reach a 52-week high following analyst upgrade
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 target. Its revisions were mixed: it raised its FY2027 loss estimate to a smaller loss of $1.34 per share, but lowered its FY2026 estimate to a larger loss of $1.48 per share and also cut estimates for Q4 2026 and Q1 2027. Septerna analyst and stock information
About Septerna
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Further Reading
- Five stocks we like better than Septerna
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
